<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12674">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941926</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011A2404</org_study_id>
    <nct_id>NCT02941926</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC</brief_title>
  <official_title>COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase IIIb study is to collect additional safety and efficacy data for
      the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2-
      advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">May 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>AEs, Grade 3/4 AEs &amp; SAEs during treatment with ribociclib + letrozole</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-Progression (TTP)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Time to progression (TTP) is defined as time from date of start of treatment to the date of event defined as the first documented progression or death due to underlying cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) for patients with measurable disease</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Overall response rate (ORR) is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>Clinical benefit rate (CBR) is defined as the proportion of patients with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcome (PRO) using scores from FACT-B questionaire</measure>
    <time_frame>Up to approximately 36 months</time_frame>
    <description>FACT-B questionnaire will be used to collect patient reported outcome data in this trial. Descriptive statistics will be used to summarize the subscale and overall scores at each scheduled assessment time point. Additionally, change from baseline at the time of each assessment will be summarized. PRO data may be summarized by country/region.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of participants with adverse events as a measure of safety and tolerability during Extension Phase</measure>
    <time_frame>Up to approximatley 30 months</time_frame>
    <description>Frequency and severity of AEs and SAEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of patients with clinical benefit during Extension Phase</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>Clinical benefit is assessed by investigator</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ribociclib + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib (LEE011)</intervention_name>
    <description>Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD</description>
    <arm_group_label>Ribociclib + letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD</description>
    <arm_group_label>Ribociclib + letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin</intervention_name>
    <description>Only for men and premenopausal women: administered as an injectable subcutaneous implant on Day 1 of each 28 days cycle</description>
    <arm_group_label>Ribociclib + letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female advanced (locoregionally recurrent or metastatic) breast cancer not
             amenable to curative therapy.

          -  In the case of women, both pre/perimenopausal and postmenopausal patients are allowed
             to be included in this study; menopausal status is relevant for the requirement of
             goserelin to be used concomitantly with ribociclib and letrozole.

               1. Postmenopausal status is defined either by:

                  I). Prior bilateral oophorectomy OR ii). Age ≥ 60 OR iii). Age &lt; 60 and
                  amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen,
                  toremifen, or ovarian suppression) and FSH and estradiol in the postmenopausal
                  range per local normal range. If patient is taking tamoxifen or toremifene and
                  age &lt; 60, then FSH and plasma estradiol levels should be in post-menopausal
                  range per local normal range.

                  Note: For women with therapy-induced amenorrhea, serial measurements of FSH
                  and/or estradiol are needed to ensure menopausal status.

               2. Premenopausal status is defined as either:

                  I). Patient had last menstrual period within the last 12 months, OR ii). If on
                  tamoxifen or toremifene within the past 14 days, plasma estradiol and FSH must
                  be in the premenopausal range per local normal range, OR iii). In case of
                  therapy induced amenorrhea, plasma estradiol and/or FSH must be in the
                  premenopausal range per local normal range.

               3. Perimenopausal status is define as neither premenopausal nor postmenopausal
                  Note: Throughout this document, perimenopausal and premenopausal status is
                  grouped together and referred as &quot;Premenopausal&quot;

          -  Patient has a histologically and/or cytologically confirmed diagnosis of
             estrogen-receptor positive and/or progesterone receptor positive breast cancer by
             local laboratory.

          -  Patient has HER2-negative breast cancer defined as a negative in situ hybridization
             test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization
             (FISH, CISH, or SISH) test is required by local laboratory testing.

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Patient has adequate bone marrow and organ function as defined by ALL of the
             following laboratory values (as assessed by local laboratory):

               -  Absolute neutrophil count ≥ 1.5 × 10^9/L

               -  Platelets ≥ 100 × 10^9/L

               -  Hemoglobin ≥ 9.0 g/dL

               -  Potassium, sodium, calcium corrected for serum albumin and magnesium within
                  normal limits or corrected to within normal limits with supplements before first
                  dose of the study medication

               -  INR ≤1.5

               -  Serum creatinine &lt;1.5 mg/dl or creatinine clearance≥50 mL/min

               -  In absence of liver metastases, alanine aminotransferase (ALT) and aspartate
                  aminotransferase (AST) should be below 2.5 × ULN. If the patient has liver
                  metastases, ALT and AST should be &lt; 5 × ULN.

               -  Total serum bilirubin &lt; ULN; or total bilirubin ≤ 3.0 × ULN with direct
                  bilirubin within normal range in patients with well-documented Gilbert's
                  Syndrome

          -  Patient must have a 12-lead ECG with ALL of the following parameters at screening:

               -  QTcF interval at screening &lt;450 msec (using Fridericia's correction)

               -  Resting heart rate ≥ 50 bpm

        Exclusion Criteria:

          -  Patient who received any CDK4/6 inhibitor

          -  Patient who received any prior systemic hormonal therapy for advanced breast cancer;
             no more than one prior regimen of chemotherapy for the treatment of metastatic
             disease is permitted

        Note:

          -  Patients who received (neo) adjuvant therapy for breast cancer are eligible. If the
             prior neo (adjuvant) therapy included letrozole or anastrozole the disease free
             interval must be greater than 12 months from the completion of treatment until study
             entry.

          -  Patients who received ≤ 28 days of letrozole or anastrozole for advanced disease
             prior to inclusion in this trial are eligible.

          -  Any prior (neo) adjuvant anti-cancer therapy or prior chemotherapy for metastatic
             disease must be stopped at least 5 half-lives or 7 days, whichever is longer, before
             study inclusion.

               -  Patient is concurrently using other anti-cancer therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari James</last_name>
      <phone>480-855-2225</phone>
      <email>KJames@ironwoodcrc.com</email>
    </contact>
    <investigator>
      <last_name>Mikhail I. Shtivelband</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly HIlls</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Watandabe</last_name>
      <phone>310-432-8900</phone>
      <email>dwatandabe@BHCancerCenter.com</email>
    </contact>
    <investigator>
      <last_name>Linnea Chap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ventura County Hematology and Oncology</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>805-485-8709</phone>
    </contact>
    <investigator>
      <last_name>Lynn Kong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Middlesex Hospital Middlesex Hospital (2)</name>
      <address>
        <city>Middletown</city>
        <state>Connecticut</state>
        <zip>06457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Slifer</last_name>
      <phone>860-358-2220</phone>
      <email>Beth.Slifer@midhosp.org</email>
    </contact>
    <investigator>
      <last_name>Robert Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Research Institute Dept of Oncology</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filiz Gokce</last_name>
      <phone>954-582-1850</phone>
      <email>Filizg@flcancercare.com</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Tan-Chiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Watson Clinic Center for Research 1730 Location</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noreen McGowan</last_name>
      <phone>863-603-4747</phone>
      <email>nmcgowan@watsonclinic.com</email>
    </contact>
    <investigator>
      <last_name>Neeharika Makani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John D. Archbold Memorial Hospital John D. Archbold Mem Hosp (4)</name>
      <address>
        <city>Thomasville</city>
        <state>Georgia</state>
        <zip>31792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Speigner</last_name>
      <phone>229-584-5400</phone>
      <email>lntaylor@archbold.org</email>
    </contact>
    <investigator>
      <last_name>Josh Simmons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates Presence Cancer Center</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Finger</last_name>
      <phone>815-725-1355</phone>
      <email>tfinger@jolietoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jason Suh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nissi George</last_name>
      <phone>201-568-5250</phone>
      <email>Nissi.George@EHMChealth.org</email>
    </contact>
    <investigator>
      <last_name>Jill Morrison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PeaceHealth St. Joseph Medical Center</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mia Johnson</last_name>
      <phone>360-788-8238</phone>
      <email>mjohnson9@peacehealth.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Nestor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Centre of Everett</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-261-3499</phone>
    </contact>
    <investigator>
      <last_name>Peter Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties Dept.ofNW Med. Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>253-396-5329</phone>
    </contact>
    <investigator>
      <last_name>Sibel Blau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3)</name>
      <address>
        <city>Cheyenne</city>
        <state>Wyoming</state>
        <zip>82001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DaNette Best</last_name>
      <phone>307-634-9311</phone>
      <email>danette.best@crmcwy.org</email>
    </contact>
    <investigator>
      <last_name>Natalie Alana Workman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerp</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussels</city>
        <zip>BE-B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sault Ste-Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverwijk</city>
        <zip>1942 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>October 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR-positive HER2-negative</keyword>
  <keyword>advanced breast cancer</keyword>
  <keyword>LEE011</keyword>
  <keyword>ribociclib</keyword>
  <keyword>letrozole</keyword>
  <keyword>goserelin</keyword>
  <keyword>CDK</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>Phase IIIb</keyword>
  <keyword>ER-positive</keyword>
  <keyword>PR-positive</keyword>
  <keyword>premenopausal</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>men with advanced breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
